Global Biopharmaceutical Company Signs Five-Year Agreement to Use Technology Suite From OmniComm Systems for Rare Disease Studies
July 31, 2019
July 31, 2019
FORT LAUDERDALE, Florida, July 31 -- OmniComm Systems issued the following news release:
Treatments for rare diseases represent approximately one-third of the drugs now under development globally, according to a new academic study. OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology, continues to expand its role in that therapeutic area with a new agreement. An international biopharmaceutical company focused on rare diseases has sig . . .
Treatments for rare diseases represent approximately one-third of the drugs now under development globally, according to a new academic study. OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology, continues to expand its role in that therapeutic area with a new agreement. An international biopharmaceutical company focused on rare diseases has sig . . .